Document:

Commercial License Agreement with IRM LLC

 [CONFIDENTIAL TREATMENT REQUESTED. CERTAIN PORTIONS OF THIS AGREEMENT HAVE BEEN REDACTED AND FILED
SEPARATELY WITH THE COMMISSION.] 
  
 Exhibit 10.17

  
 COMMERCIAL LICENSE AGREEMENT 
  
 This Agreement (the “Agreement”) effective as of July 12, 2000 (the
“Effective Date”) is made by and between Xenogen Corporation, having a principal place of business at 860 Atlantic Avenue, Alameda, California 94501 (“Xenogen”) and IRM, LLC, a Delaware Corporation, (“IRM”), having a
principal place of business at Sofia House, 48 Church Street, Hamilton, Bermuda. 
  
 BACKGROUND 
  
 A. Xenogen has
expertise in the development and detection of living cells, organisms and transgenic animals that have the property of bioluminescence, and owns or has rights to intellectual property relating thereto. 
  
 B. IRM wishes to obtain a non-exclusive commercial license to the Xenogen
Technology for use in the Field at the Authorized Sites (capitalized terms defined below). 
  
 NOW, therefore, the parties agree as follows: 
  
 1. Definitions. 
  
 “Xenogen Monitoring
Technology” means (i) U.S. Patent No. 5,650,135; (ii) all divisions, substitutions, continuations, and continuation-in-part applications of (i); (iii) all foreign counterparts of any of the preceding; and (iv) all patents issuing on any of the
preceding, including reissues, reexaminations and extensions; which patents and applications have been licensed to Xenogen pursuant to that certain exclusive license agreement between Xenogen and The Board of Trustees of the Leland Stanford Junior
University (“Stanford”) effective July 1,1997. 
  
 “Xenogen Technology” means (i) all patents and patent applications owned or controlled by Xenogen that relate to the practice of in vivo imaging; (ii) all divisions, substitutions, continuations, and continuation-in-part
applications of (i); (iii) all foreign counterparts of any of the preceding; (iv) all patents issuing on any of the preceding, including reissues, reexaminations and extensions; and (v) all future patents and patent applications relating to the
practice of in vivo imaging. Xenogen Technology includes the Xenogen Monitoring Technology. 
  
 “Field” means the activities specified in Exhibit A attached hereto. 
  
 “Authorized Site(s)” means the physical location(s) specified in Exhibit B attached hereto. 
  
 “Affiliate” means Novartis Pharmaceuticals Corporation
(“Novartis”) or any corporation, firm, partnership or other legal entity which, directly or indirectly, controls, is controlled by or is under common control by or with Novartis. For the purposes of this definition, “control”
shall mean the direct or indirect ownership of more than 50% of the outstanding voting securities or capital stock of such entity or any other comparable equity or ownership interest. 
  
 “System” means an imaging system as specified in Exhibit C attached hereto. 
  

 1 

 “Permitted Users” shall mean IRM, Novartis, Novartis Research Foundation, the Novartis
Institute for Functional Genomics Inc., the Friedrich Miescher Institute and all Novartis Affiliates. 
  
 “Commercial Use License” means a license by Xenogen granting rights to any for-profit entity to use the Xenogen Monitoring Technology for
commercial drug-development (e.g., compound screening and/or target validation) purposes. It is agreed that the following types of licenses do not constitute a Commercial Use License: (i) an evaluation license granted for the purpose of evaluating
Xenogen’s technology and/or BiowareTM
organisms, such as the September 1998 agreement between the parties executed by Novartis Pharmaceuticals Corporation on September 18, 1998, and by Xenogen on September 25, 1998; (ii) a strain development or modification agreement, whereby a third
party is licensed to use the Xenogen Monitoring Technology to develop new BiowareTM organisms or improve existing BiowareTM organisms, without rights to use such BiowareTM organisms for its own or contract research drug development purposes; and (iii) a distribution agreement, whereby a third party is granted rights to use the Xenogen Monitoring Technology in connection with the
distribution certain Xenogen BiowareTM organisms or
animals to third parties, without rights to use such BiowareTM organisms or animals for its own or contract research drug development purposes. 
  
 2. License Grant. 
  
 2.1 License. Xenogen hereby grants to IRM and Permitted Users, a non-exclusive, non-transferable license, without right to grant or authorize any
sublicenses, to use the Xenogen Technology solely in the Field solely at the Authorized Sites. 
  
 2.2 No Implied Rights: Retained Rights. Only the License granted pursuant to the express terms of this Agreement shall be of any legal force or effect. No other license rights shall be granted or created by
implication, estoppel or otherwise. Xenogen reserves the right to license the Xenogen Technology to others, and to use the Xenogen Technology for its own purposes. 
  
 2.3 No Warranty. IRM ACKNOWLEDGES THAT NEITHER XENOGEN NOR STANFORD MAKE ANY REPRESENTATIONS OR EXTEND ANY WARRANTIES
OF ANY KIND, WHETHER EXPRESS OR IMPLIED, WITH RESPECT TO THE XENOGEN TECHNOLOGY, INCLUDING WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, OR THAT THE USE OF THE XENOGEN TECHNOLOGY WILL NOT INFRINGE THE INTELLECTUAL PROPERTY RIGHTS
OF THIRD PARTIES. 
  
 3. Light-Emitting Organisms. 
  
 3.1 Source. IRM and Permitted Users may develop or otherwise acquire
from any source, light-emitting organisms for use in the practice of the License. 
  
 3.2 Existing Xenogen BiowareTM Organisms. IRM and Permitted Users may license or purchase from Xenogen any BiowareTM organisms that Xenogen has available for third party licensing or purchase, respectively, at the then current list price for such BiowareTM organisms; *** 
  
 *** Confidential Treatment Requested 
  

 2 

 3.3 Custom Xenogen BiowareTM Organisms. The parties may agree to have Xenogen develop custom BiowareTM organisms for IRM or Permitted Users on terms and conditions to be negotiated in good
faith. 
  
 4. CCD Imaging System 
  
 4.1 Available Systems. Xenogen shall offer for sale or lease to IRM
and Permitted Users the Systems specified in Exhibit C, on terms and conditions to be agreed upon by the parties. 
  
 4.2 Lease. IRM and Permitted Users may lease either of the Systems specified in Exhibit C at a cost of *** per month per System. The lease price
includes on-site installation and the cost of service reasonably necessary to maintain the leased System in proper operating condition. 
  
 4.3 Purchase. IRM and permitted Users may purchase either of the Systems specified in Exhibit C at a per-System cost of *** (Hamamatsu) or ***
(IVISTM). The purchase cost of each System includes
on-site installation and one year of service and maintenance at no additional charge. 
  
 4.4 Hardware Upgrades. Xenogen shall notify IRM or Permitted Users if additional hardware with enhanced functionality for in vivo imaging (“Hardware Upgrade”) becomes available from Xenogen. At
IRM’s or Permitted Users’ option, the parties shall then negotiate in good faith the terms on which such a Hardware Upgrade could be made available to IRM or Permitted Users. *** 
  
 4.5 Service Agreement. Xenogen will make available to IRM and
Permitted Users a service agreement on terms consistent with industry norms (including standard FTE labor and parts charges and travel expenses) to provide for the service and maintenance of any System(s) purchased by IRM or Permitted Users after
expiration of the one year free service. Service will be initiated at IRM’s or Permitted Users’ request, on terms and conditions to be agreed upon by the parties. 
  
 4.6 Software License. Contingent upon the lease or purchase of at least one System by IRM or Permitted Users, Xenogen
shall grant to IRM and Permitted Users a nonexclusive, nontransferable license to use and display the Software with the Equipment and with up to five (5) additional desktop computers (per System leased or purchased) used for analysis of data
obtained using the System at the Authorized Sites for the duration of this Agreement. 
  
 4.7 Software Upgrades. Xenogen will provide to IRM and Permitted Users, without charge, any upgrades to the Software (“Software Upgrades”) that Xenogen makes available to third parties. 
  
 4.8 New Software. If Xenogen makes available to third parties any new
software suitable for use with in vivo imaging (“New Software”), Xenogen shall make the New Software available to IRM and Permitted Users on terms and conditions at least as favorable as the terms and conditions agreed to by any
commercial entity that has in place a Commercial Use License to the 
  
 ***
Confidential Treatment Requested 
  

 3 

 
Xenogen Monitoring Technology, for similar quantities of New Software within six (6) months of when the New Software becomes available to IRM and Permitted
Users. 
  
 4.9 Acknowledgement. The copyright of the
Software is and shall remain owned by Xenogen, and IRM and Permitted Users agree that they will not, without Xenogen’s prior written consent, directly or indirectly, modify, make derivative works of, or make any copies of the Software, except
those copies necessary to run the software pursuant to Section 4.6 herein. IRM and Permitted Users further agree that they shall not, directly or indirectly, attempt to reverse engineer or decompile the Software or otherwise derive source code from
the Software. 
  
 4.10 Limited Warranty. Xenogen warrants
that any System leased or purchased from Xenogen by Novartis will include all components necessary for conducting in vivo imaging experiments. 
  
 4.11 Disclaimer of All Other Warranties. XENOGEN’S LIMITED WARRANTY SET FORTH IN SECTION 4.10 IS THE EXCLUSIVE WARRANTY, AND XENOGEN MAKES NO
OTHER WARRANTIES (EXPRESS, IMPLIED, STATUTORY OR OTHERWISE) WITH RESPECT TO THE SYSTEM TRANSFERRED HEREUNDER, AND SPECIFICALLY DISCLAIMS ANY AND ALL IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE, AND ALL WARRANTIES OF
NONINFRINGEMENT OF THIRD PARTY INTELLECTUAL PROPERTY RIGHTS. 
  
 5. Consideration. In consideration for the License provided to IRM herein, IRM shall pay to Xenogen by wire transfer to an account designated by Xenogen a fee (“Fee”) of two (2) million U.S. dollars (U.S. $2,000,000.00) per
year for each of three (3) years. Such payments will be due within fifteen (15) business days of each yearly anniversary of the Effective Date. The first payment shall be due within fifteen (15) business days of the Effective Date. 
  
 6. Ownership of Intellectual Property. IRM and Permitted Users agree
that all intellectual property rights relating to the Xenogen Monitoring Technology, the System(s) and their uses are and shall be owned or controlled exclusively by Xenogen. Xenogen agrees that all invention(s) made by IRM or the Permitted Users in
connection with the License granted hereunder that relate to subject matter other than the Xenogen Monitoring Technology, the System, or their uses shall be owned exclusively by IRM or Novartis. 
  
 7. Confidentiality. 
  
 7.1 Confidential Information. Except as expressly provided herein, the parties agree that, for the term of this
Agreement and for three (3) years thereafter, the receiving party shall protect from disclosure and shall not use for any purpose except for the purposes contemplated by this Agreement, any information identified as confidential (“Confidential
Information”) furnished to it by the disclosing party hereto. The receiving party shall use the same standard of care in safeguarding the disclosing party’s information as the receiving party uses for its own similarly sensitive
information. Confidential Information shall not include information which the receiving party shows: 
  
 (a) was already known to the receiving party, other than under an obligation of confidentiality, at the time of disclosure; 
  

 4 

 (b) was generally available to the public or otherwise part of the public domain at the
time of its disclosure to the receiving party; 
  
 (c) became generally available to the public or otherwise part of the public domain after its disclosure and other than through any act or omission of the receiving party in breach of this Agreement; 
  
 (d) was subsequently lawfully disclosed to the receiving
party by a person other than a party hereto; or 
  
 (e) was approved for release by written authorization of the disclosing party. 
  
 7.2 Permitted Use and Disclosures. Each party hereto may use or disclose information disclosed to it by the other party to the extent such use or disclosure is reasonably necessary in complying with applicable
law, legal process or governmental regulations, or exercising its rights hereunder, provided that if a party is required to make any such disclosure of another party’s Confidential Information, it will give reasonable advance notice to the
latter party of such disclosure and will use its best efforts to secure confidential treatment of such information prior to its disclosure (whether through protective order or otherwise). 
  
 7.3 Confidential Terms. Except as expressly provided herein, each party agrees not to disclose any terms of this
Agreement to any third party without the consent of the other party; provided, disclosures may be made to actual or prospective corporate partners or investors, or to a party’s accountants, attorneys and other professional advisors. Any
disclosures made to actual or prospective corporate partners or investors, or to a party’s accountants, attorneys and other professional advisors, shall be limited to statements of fact and shall not imply endorsement of the other party’s
products or services. 
  
 8. Press Release. Xenogen may make a press
release in the form attached as Exhibit D to announce the execution of this Agreement; thereafter, Xenogen and IRM may each disclose to third parties the information contained in such press release without the need for further approval by the other
party. Other press releases of any kind by either party will be released only after both parties have agreed in writing to the contents of the press releases. 
  

9. Warranties and Indemnification 
  
 9.1 Warranty of Right to Grant License. Xenogen warrants that as of the Effective Date, (a) it has the legal right to grant the License herein, and
(b) the grant of the License does not conflict with, violate, or constitute a breach or default under any contract or other obligation of Xenogen. 
  
 9.2 Warranty of Full Disclosure. Xenogen warrants that as of the Effective Date, all non-cumulative material, prior art references and information
that Xenogen is aware of and that could adversely affect Xenogen’s pending patent applications and issued patents relating to the Xenogen Monitoring Technology are presently before the United States Patent and Trademark Office (USPTO).

  
 9.3 Indemnification. (a) IRM agrees to indemnify,
defend and hold Xenogen and its directors, officers, employees and agents and The Trustees of the Leland Stanford Junior 

  

 5 

 
University, Stanford Health Services and their respective trustees, officers, employees, students and agents (the “Xenogen Indemnitee(s)”) harmless
from and against any and all liabilities, claims, demands, expenses (including, without limitation, reasonable attorneys and professional fees and other costs of litigation), losses or causes of action (each, a “Xenogen Liability”) that
may be brought against the Xenogen Indemnitee(s) by reason or arising out of or relating in any way to (i) IRM’s or Permitted Users’ possession and use of the System, whether based on negligence, product liability or otherwise, (ii) the
exercise of any right granted to IRM or Permitted Users pursuant to this Agreement, or (iii) any material breach of this Agreement by IRM or Permitted Users, except to the extent, in each case, that such Xenogen Liability is caused by the negligence
or willful misconduct by Xenogen as determined by a court of competent jurisdiction. Notwithstanding the above, neither IRM nor any Permitted User shall enter into any settlement or other agreement which makes any admission of negligence or
wrongdoing on the part of any Xenogen Indemnitee or that relates to the validity or enforceability of any patents owned by Xenogen without the prior written consent of Xenogen, which consent shall not be unreasonably withheld. (b) Xenogen agrees to
defend, indemnify and hold IRM, the Permitted Users and its directors, officers, employees, agents and assigns (the “IRM Indemnitee(s)”) harmless against any and all liabilities, claims, demands, expenses (including, without limitation,
reasonable attorney’s and professional fees and other costs of litigation), losses or causes of action (each, an “IRM Liability”) that may be brought against the IRM Indemnitee(s) by reason or arising out of or relating in any way to
any negligent act or willful misconduct on the part of Xenogen, except to the extent that such IRM Liability is caused by the negligence or willful misconduct by IRM or Permitted Users as determined by a court of competent jurisdiction.
Notwithstanding the above, Xenogen shall not enter into any settlement or other agreement which makes any admission of negligence or wrongdoing on the part of any IRM Indemnitee(s). The party seeking indemnification under this Section shall
immediately notify the other party, in writing, of any claim or proceeding brought against it for which it seeks indemnification hereunder. 
  
 10. Term and Termination 
  
 10.1 Term. This Agreement will commence on the Effective Date and unless terminated earlier as provided in this Article 10, will terminate three
(3) years after the Effective Date. 
  
 10.2 Term
Extension. Prior to the *** anniversary of the Effective Date, unless earlier terminated, IRM, Permitted Users or an assignee under Section 11.2 herein may extend the Term for up to *** additional years by paying to Xenogen a fee of *** U.S.
dollars (U.S. ***) per year of extension. 
  
 10.3 Permissive
Termination. IRM may terminate this Agreement upon thirty (30) days written notice to Xenogen for (i) failure of the Xenogen Monitoring Technology, as confirmed by at least one peer-reviewed publication by a disinterested party, (ii) a final
judgment of invalidity of all Relevant Patent Claims (as defined below) under the Xenogen Monitoring Technology, (iii) a final adverse resolution of infringement of third party intellectual property rights, or (iv) an assignment by Xenogen to a
major pharmaceutical company pursuant to Section 11.2 herein. A Relevant Patent Claim is a claim under the Xenogen Monitoring Technology that would be infringed by IRM or Permitted Users but for the License granted herein. IRM may also terminate
this Agreement after two years, and annually thereafter, for any reason with 60 days written notice prior to the annual anniversary date of this Agreement. 
  
 *** Confidential Treatment Requested 
  

 6 

 10.4 Termination for Cause. Either party may terminate this Agreement in the event the other party
has materially breached or defaulted in the performance of any of its obligations hereunder, and such default has continued for thirty (30) days after written notice thereof was provided to the breaching party by the non breaching party. Any
termination shall become effective at the end of such thirty (30) day period unless the breaching party has cured any such breach or default prior to the expiration of such period. Notwithstanding the above, in the case of a failure to pay any
amount due hereunder the period for cure of any such default following notice thereof shall be ten (10) days and, unless payment is made within such period, the termination shall become effective at the end of such period. 
  
 10.5 Automatic Termination. This Agreement shall terminate
automatically and without further notice to the other party in the event that either party shall make any unauthorized assignment for the benefit of creditors, file any petition under the bankruptcy or insolvency laws of any jurisdiction, have or
suffer a receiver or trustee to be appointed for its business or property, or be adjudicated a bankrupt or an insolvent. 
  
 10.6 Effect of Termination. 
  
 (a) Accrued Rights and Obligations. Termination of this Agreement for any reason shall not release any party hereto from any
liability which, at the time of such termination, has already accrued to the other party or which is attributable to a period prior to such termination nor preclude either party from pursuing any rights and remedies it may have hereunder or at law
or in equity with respect to any breach of this Agreement. 
  
 (b) Return of Confidential Information and Leased Systems. Upon any termination or expiration of this Agreement, IRM and Permitted Users and Xenogen shall promptly return to the other party all Confidential
Information received from the other party (except one copy which may be retained for legal archival purposes). IRM and Permitted Users shall return to Xenogen all leased Systems, including all Equipment and Software leased to IRM and Permitted Users
under any lease agreement within thirty (30) days of the termination of this Agreement. The System(s) shall be shipped to Xenogen’s facility at the address set forth in Section 11.5. IRM or Permitted Users shall pay all shipping and freight
charges, and shall assume the risk of loss during shipment. Xenogen agrees that in the event of any loss or damage to the leased System(s), IRM’s or Permitted Users’ liability for such loss or damage shall not exceed the lower of the
amortized or market values of the leased System(s) at the time of damage or loss. 
  
 (c) Licenses. The licenses granted hereunder shall terminate upon the termination of this Agreement. 
  
 10.7 Survival. Sections 2.3, 4.11, 10.6 and 10.7; and Articles 6, 7, 9
and 11 of this Agreement shall survive the expiration or termination of this Agreement for any reason. 
  
 11. Miscellaneous 
  
 11.1
Governing Law; Venue. This Agreement and any dispute, including without limitation any arbitration, arising from the performance or breach hereof shall be governed by and construed and enforced in accordance with the laws of the state of
California, without reference to conflicts of laws principles. The exclusive venue of any dispute arising out of or in connection with 

  

 7 

 
the performance or breach of this Agreement shall be the California state courts or U.S. district court located in Alameda County, California. 
  
 11.2 Assignment. IRM may not transfer or assign this Agreement or any
of IRM’s rights hereunder without the written consent of Xenogen, which consent shall not be unreasonably withheld; the foregoing notwithstanding, IRM may assign this Agreement to Novartis or any Novartis Affiliate. Xenogen may assign this
Agreement or its rights hereunder. This Agreement shall be binding upon and inure to the benefit of the parties and their permitted successors and assigns. 
  
 11.3 Waiver. No waiver of any rights, shall be effective unless consented to in writing by the party to be charged and the waiver of any breach or
default shall not constitute a waiver of any other right hereunder or any subsequent breach or default. 
  
 11.4 Severability. In the event that any provision of this Agreement is determined to be invalid or unenforceable by a court of competent
jurisdiction, the remainder of the Agreement shall remain in full force and effect without said provision. 
  
 11.5 Notices. All notices, requests and other communications hereunder shall be in writing and shall be personally delivered or sent by telecopy or
other electronic facsimile transmission or by registered or certified mail, return receipt requested, postage prepaid, in each case to the respective address specified below, or such other address as may be specified in writing to the other parties
hereto: 
  

					
	 	 	IRM:	  	 IRM, LLC
 P. O. Box HM 2899
 Hamilton HMLX, Bermuda

			
	 	 	Xenogen:	  	 Xenogen Corporation
 860 Atlantic Avenue
 Alameda, CA 94501
 Attn: President

  
 11.6 Independent
Contractors. Both parties are independent contractors under this Agreement. Nothing contained in this Agreement is intended nor is to be construed so as to constitute Xenogen or Novartis as partners or joint venturers with respect to this
Agreement. Neither party shall have any express or implied right or authority to assume or create any obligations on behalf of or in the name of the other party or to bind the other party to any other contract, agreement, or undertaking with any
third party. 
  
 11.7 Use of Name. Neither IRM nor
Permitted Users shall use the name or trademarks of Xenogen or Stanford without the prior written consent of Xenogen or Stanford, respectively. Xenogen shall not use the name or trademarks of IRM or the Permitted Users without prior written consent,
respectively. 
  
 11.8 Compliance with Laws. In exercising
their rights under this license, the parties shall fully comply in all material respects with the requirements of any and all applicable laws, regulations, rules and orders of any governmental body having jurisdiction over the exercise of rights
under this Agreement. 
  

 8 

 11.9 LIMITATION OF LIABILITY. NEITHER PARTY SHALL BE LIABLE TO THE OTHER FOR ANY SPECIAL,
CONSEQUENTIAL, INCIDENTAL OR INDIRECT DAMAGES, INCLUDING, WITHOUT LIMITATION, ANY LOSS OF USE, REVENUE OR PROFIT, ARISING OUT OF THIS AGREEMENT, THE EXECUTION OF THE LICENSE, OR ANY BREACH OR DEFAULT UNDER THIS AGREEMENT, HOWEVER CAUSED, UNDER ANY
THEORY OF LIABILITY. 
  
 11.10 “Most Favored
Licensee”. Xenogen agrees that it will not grant, to any commercial entity, a Commercial Use License with no milestone, royalty or per-use fees, to use the Xenogen Technology for All Fields, for a per-year license fee which is less than the
per-year license fee paid by IRM under this Agreement. In the event that Xenogen does grant such a license to any other commercial entity, Xenogen will refund or credit IRM the difference. This clause shall not apply to any settlements for past
infringement. 
  
 11.11 Entire Agreement; Amendment. This
Agreement, together with its Exhibits, constitutes the entire and exclusive Agreement between the parties with respect to the subject matter hereof and supersedes and cancels all previous discussions, agreements, commitments and writings in respect
thereof. No amendment or addition to this Agreement shall be effective unless reduced to writing and executed by the authorized representatives of the parties. 
  

									
	 IRM, LLC
	 	 	 	 XENOGEN CORPORATION

					
	Signature:	 	/s/ Dr. J. Reinhardt         /s/ Dr. B. Aebischer	 	 	 	Signature:	 	/s/ David W. Carter
	 	 	
	 	 	 	 	 	

	Printed Name:	 	Dr. J. Reinhardt              Dr. B. Aebischer	 	 	 	Printed Name:	 	David W. Carter
	Title:	 	President                         Secretary	 	 	 	Title:	 	Chairman
	Date:	 	                         7/25/2000
	 	 	 	Date:	 	7/10/00

  
 Exhibit A: Field 
 Exhibit B: Authorized Site 
 Exhibit C: CCD Imaging System 
 Exhibit D: Press Release 
  

 9 

 EXHIBIT A 
  

Field 
  
 Drug discovery, lead compound development, pre-clinical evaluation & development (including efficacy and safety assessment, such as toxicology), and clinical research & development for all targets, diseases
and indications. 
  

 EXHIBIT B 
  

Authorized Sites 
  
 All Novartis sites 
 The sites of all Novartis Affiliates 
 The Novartis Research Foundation entities including, but not limited to: 
 The Novartis Institute for Functional Genomics, and 
 The Friedrich Miescher Institute. 
  

 EXHIBIT C 
  
 CCD Imaging Systems Available for Sale or Lease to IRM or Permitted Users 
  
 Hardware 
  
 Hamamatsu 2400 Imaging System 
  

	 	•	Hamamatsu intensified CCD camera 

  

	 	•	Hamamatsu (Argus) Image Processor 

  

	 	•	Nikkor® 50 mm f 1.2 lens 

  

	 	•	Hamamatsu specimen chamber 

  

	 	•	Macintosh® control computer with high-resolution monitor 

  
 Xenogen IVISTM
Imaging System 
  

	 	•	Roper LN-1300EB cooled CCD camera (or equivalent) 

  

	 	•	Navitar 50 mm f 0.95 lens (or equivalent) 

  

	 	•	Xenogen specimen chamber 

  

	 	•	Windows 98® control computer with high-resolution monitor 

  
 Software 
  
 LivingImageTM image processing and data
analysis software 
  

 AMENDMENT TO COMMERCIAL LICENSE AGREEMENT 
  
 THIS AMENDMENT, effective as of July 12, 2003, (the “Effective Date”), is made by and between Xenogen Corporation, having
principal place of business at 860 Atlantic Avenue, Alameda, California 94501 (“Xenogen”) and Novartis Institutes for BioMedical Research, Inc., a Delaware corporation having a principal place of business at 400 Technology Square,
Cambridge, Massachusetts 02139 (“NIBRI”). 
  
 WITNESSETH

  
 WHEREAS, Xenogen and IRM, LLC, a Delaware corporation, are parties to a
Commercial License Agreement, effective as of July 12, 2000 (the “License Agreement”); 
  
 WHEREAS, NIBRI is an “Affiliate” of IRM and a “Permitted User” under the License Agreement, as the terms “Affiliate” and “Permitted User” are defined in the License Agreement;

  
 WHEREAS, NIBRI has the right under section 10.2 of the License Agreement to
extend the term of the license agreement for up to four additional years by payment of a specified fee; 
  
 WHEREAS, NIBRI wishes to extend the License Agreement for two additional years and Xenogen and NIBRI have agreed upon a fee and payment schedule for such additional years that are different from those provided for in
the License Agreement; and 
  
 WHEREAS, the parties wish to amend certain other
terms and provisions of the License Agreement; 
  
 NOW, THEREFORE, the parties
agree as follows: 
  

	 	1.	Capitalized terms used but not defined herein shall have the meanings ascribed to them in the License Agreement. 

  

	 	2.	The Term of the License Agreement is hereby extended for two years beginning upon the Effective Date of this Amendment (the “Extension Term”). 

  

	 	3.	NIBRI or an Affiliate will pay to Xenogen a fee of *** for the Extension Term. Such fee will be due 60 days after the Effective Date. The payment of such fee by NIBRI or an
Affiliate shall be in lieu of the payment of fees by IRM for the Extension Term. 

  

	 	4.	Prior to the end of the Extension Term, unless earlier terminated, IRM, Permitted Users or an assignee under section 11.2 of the License Agreement may extend the Extension Term for
up to two additional years by paying to Xenogen a fee of *** per year of extension. 

  

	***	Confidential Treatment Requested 

	 	5.	Section 11.10 of the License Agreement is hereby amended to read as follows: 

  

11.10 *** 
  

	 	6.	The first sentence of the definition of Commercial Use License in Section 1 of the License Agreement is amended to read as follows: 

  
 “Commercial Use License” means an enterprise-wide, unlimited use
license by Xenogen granting rights to any for-profit entity to use the Xenogen Monitoring Technology for commercial drug-development (e.g., compound screening and/or target validation) purposes.” 
  

	 	7.	Sections 4.1 through 4.3 of the License Agreement are hereby deleted and replaced with the following: 

  
 “4.1 Xenogen will make available its IVIS® Imaging System 100 available for purchase by IRM or Permitted Users for *** during calendar year 2003 and for *** for
the remaining term of this Agreement.” 
  
 The remaining
subsections 4.4 through 4.11 of the License Agreement are renumbered 4.2 through 4.9. 
  

	 	8.	Except as amended hereby, the License Agreement shall remain in full force and effect, according to its terms. 

  

	 	9.	This Amendment, and the License Agreement as amended, shall constitute the entire agreement between the parties and shall supersede all other agreements, whether written or oral,
relating to the subject matter hereof. 

	***	Confidential Treatment Requested 

 IN WITNESS WHEREOF, the parties have entered into this Amendment effective as of July 12, 2003, by signatures of their
duly authorized officers set forth below. 
  
 NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. 
  

			
	By:	 	 [Signature Illegible]

		
	 Title:
	 	 VICE PRESIDENT

  
 XENOGEN CORPORATION 
  

			
	By:	 	 /s/    David W. Carter

		
	 Title:
	 	 CEOLicense Agreement with Promega Corporation

 [CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS AGREEMENT HAVE BEEN REDACTED AND HAVE BEEN FILED
SEPARATELY WITH THE COMMISSION.] 
  
 EXHIBIT 10.18

  
 LICENSE AGREEMENT 
  
 THIS AGREEMENT is made this 20th day of March, 2003 by and between PROMEGA
CORPORATION, a corporation organized and existing under the laws of the State of Wisconsin and with principal offices located at 2800 Woods Hollow Road, Madison, Wisconsin, 53711 (“PROMEGA”) and Xenogen Corporation, a corporation organized
and existing under the laws of the State of Delaware with principal offices located at 860 Atlantic Avenue, Alameda, California, 94501 (“XENOGEN”) 
  
 WHEREAS PROMEGA is in the owner by assignment of all right, title and interest in United States Patent No. 5,670,356 which issued September 23, 1997;
(there being no foreign patent applications or issued patents corresponding thereto) and in the inventions described and claimed therein; and 
  
 WHEREAS XENOGEN owns or controls certain patent rights regarding in vivo imaging of bioluminescence and bacteria and cells that may be used for such
imaging; and 
  
 WHEREAS XENOGEN desires to sell PROMEGA LICENSED
PRODUCTS to its customers for such customers’ use of PROMEGA LICENSED PRODUCTS and the PROMEGA LICENSED PATENT RIGHTS in the XENOGEN FIELD OF USE in addition to XENOGEN’s biophotonic imaging technology; 
  
 WHEREAS PROMEGA desires to manufacture, use, sell and promote XENOGEN
LICENSED PRODUCTS to its academic and not-for-profit customers for such customers’ use of XENOGEN LICENSED PRODUCTS and the XENOGEN LICENSED PATENT RIGHTS in the PROMEGA FIELD OF USE in conjunction with XENOGEN’s biophotonic imaging
technology; and 
  
 WHEREAS each Party desires to grant a
sublicense to the other Party hereto in accordance with the principles set forth hereinabove and under the terms of the Agreement. 
  
 NOW, THEREFORE in consideration of the foregoing premises, the Parties agree as follows: 
  
 1. DEFINITIONS 
  
 1.1 AFFILIATE means any corporation or other business entity in which a Party owns or controls, directly or indirectly, at least fifty percent (50%) of the outstanding
stock or other voting rights entitled to direct business decisions; provided however, that in any country where the local law shall not permit foreign equity participation of at least fifty percent (50%), then AFFILIATE shall include any company in
which the a Party shall own or control, directly of indirectly, the maximum percentage of such outstanding stock or voting rights permitted by local law. 
  

 Page 1 of 29 

 1.2 EFFECTIVE DATE is the date first set forth herein above. 
  
 1.3 XENOGEN FIELD OF USE means use as a research reagent for imaging of bioluminescence,
either in whole-animals, or outside of whole animals, provided that, with respect to XENOGEN’s customers, the latter use does not involve extraction of, or molecular alterations to, the PROMEGA LICENSED TECHNOLOGY from within a PROMEGA LICENSED
PRODUCT. It is understood and agreed by the Parties that, as used herein, the term “research reagent” means and refers to use in life sciences research, including, but not limited to, research comprising screening of substances for their
biological and toxicological effects. Diagnostic or therapeutic uses are specifically excluded from this XENOGEN FIELD OF USE definition. 
  
 1.4 PROMEGA FIELD OF USE means use by academic institutions or not-for-profit entities as a research reagent for imaging of bioluminescence in whole-animals. It is
understood and agreed by the Parties that, as used herein, the term “research reagent” means and refers to use in life sciences research, including, but not limited to, research comprising screening of substances for their biological and
toxicological effects. Diagnostic or therapeutic uses are specifically excluded from this PROMEGA FIELD OF USE definition. 
  
 1.5 PROMEGA LICENSED METHOD means any method that is covered by PROMEGA LICENSED PATENT RIGHTS, or the use of which would constitute, but for the license granted to
XENOGEN pursuant to this Agreement, an infringement of any pending or issued claim within the PROMEGA LICENSED PATENT RIGHTS. 
  
 1.6 PROMEGA LICENSED PATENT RIGHTS means patent rights to any subject matter falling within the scope of the claims of the patents set forth in “Appendix A –
Promega’s Patents” which is attached to this Agreement and made a part hereof; and any continuing applications thereof including divisions and substitutions but excluding claims in continuation-in-part applications to the extent they
contain claimed subject matter other than that adequately supported in the issued patents listed hereinabove; and any patents or reissues issuing on said patents or continuing applications with claims which have not been found invalid or
unenforceable by a court of law or agency of competent jurisdiction from which an appeal has not been or cannot be taken; any and all of which shall be automatically incorporated and added to this Agreement and shall periodically be added to said
Appendix A. 
  
 1.7 PROMEGA LICENSED PRODUCT means any material, product or kit
that: (a) incorporates the PROMEGA LICENSED TECHNOLOGY; and at the same time (b) is a living biological cell, microorganism or transgenic animal; and also at the same time (c) either is claimed by the PROMEGA LICENSED PATENT RIGHTS, or whose
manufacture, use, or sale would constitute, but for the license granted to XENOGEN pursuant to this Agreement an infringement of a VALID CLAIM within the PROMEGA LICENSED PATENT RIGHTS. Specifically excluded from this PROMEGA LICENSED PRODUCTS
definition are nonliving products, including but not limited to, 

  

 Page 2 of 29 

 
viruses, bacteriophages, plasmid vectors, and free or complexed nucleic acids comprising the luciferase gene sequence, and mixtures, formulations or extracts
containing the luciferase enzyme. 
  
 1.8 PROMEGA LICENSED SERVICE means any
service, process or procedure that: (i) uses a PROMEGA LICENSED PRODUCT in the course of performing such service, process or procedure; or (ii) includes the use of a PROMEGA LICENSED METHOD in conjunction with the PROMEGA LICENSED TECHNOLOGY in the
course of performing such service, process or procedure. 
  
 1.9 PROMEGA LICENSED
TECHNOLOGY means the modified firefly luciferase gene comprising the DNA sequence and corresponding amino acid sequence of the luciferase enzyme derived therefrom to the extent that such sequences fall within the scope of at least one VALID CLAIM
under the PROMEGA LICENSED PATENT RIGHTS which are set forth in “Appendix B – Sublicensed Technology” which is attached hereto and incorporated herein by reference. All other luciferases, either encoded by alternative DNA sequences,
or comprised of alternative amino acid sequences, or both, other than is shown in Appendix B are specifically excluded from this Agreement. 
  
 1.10 NET SALES OF PROMEGA LICENSED PRODUCT means the invoiced sale price received by XENOGEN or its AFFILIATES for PROMEGA LICENSED PRODUCTS sold by XENOGEN or its
AFFILIATES, respectively, hereunder to third parties, less the sum of the following actual and customary deductions where applicable: cash, trade, or quantity discounts; sales, use, tariff, import/export duties or other excise taxes imposed upon
particular sales; transportation charges; and allowances or credits to customers because of rejections or returns. 
  
 1.11 NET SALES OF PROMEGA LICENSED SERVICE means the invoiced sale price received by XENOGEN or its AFFILIATES for PROMEGA LICENSED SERVICES performed by XENOGEN or its
AFFILIATES, respectively, hereunder for third parties on a fee-for-service basis, less the sum of the following: cash, trade, or quantity discounts; sales, use, tariff, import/export duties or other excise taxes imposed upon particular sales;
transportation charges; allowances or credits to customers because of rejections or returns; and the fully burdened costs of providing such PROMEGA LICENSED SERVICES. 
  
 1.12 NET SALES OF XENOGEN LICENSED PRODUCT means the invoiced sale price received by PROMEGA or its AFFILIATES for XENOGEN LICENSED PRODUCTS
sold by PROMEGA or its AFFILIATES, respectively, hereunder to third parties, less the sum of the following actual and customary deductions where applicable: cash, trade, or quantity discounts; sales, use, tariff, import/export duties or other excise
taxes imposed upon particular sales; transportation charges; and allowances or credits to customers because of rejections or returns. 
  
 1.13 NET SALES OF XENOGEN LICENSED SERVICE means the invoiced sale price received by PROMEGA or its AFFILIATES for XENOGEN LICENSED SERVICES 

  

 Page 3 of 29 

 
performed by PROMEGA or its AFFILIATES, respectively, hereunder for third parties on a fee-for-service basis, less the sum of the following: cash, trade, or
quantity discounts; sales, use, tariff, import/export duties or other excise taxes imposed upon particular sales; transportation charges; allowances or credits to customers because of rejections or returns; and the fully burdened costs of providing
such XENOGEN LICENSED SERVICES. 
  
 1.14 TERM means the period during which the
Agreement is in force and, unless terminated sooner in accordance with Article 9 (LIFE OF THE AGREEMENT), extending from the EFFECTIVE DATE until the date that neither the manufacture, sale nor use of any PROMEGA LICENSED PRODUCT or XENOGEN LICENSED
PRODUCT is covered by a VALID CLAIM. 
  
 1.15 TERRITORY means worldwide.

  
 1.16 VALID CLAIM means a claim of an issued and unexpired patent within the
PROMEGA LICENSED PATENT RIGHTS or XENOGEN LICENSED PATENT RIGHTS in a specific country which has not been held unpatentable, invalid or unenforceable by a court or other government agency of competent jurisdiction from which no appeal can or has
been taken and has not been admitted to be invalid or unenforceable through reissue, re-examination, disclaimer or otherwise; provided, however, that if the holding of such court or agency is later reversed by a court or agency with overriding
authority, the claim shall be reinstated as a VALID CLAIM with respect to NET SALES made after the date of such reversal. 
  
 1.17 XENOGEN IMAGING PATENT RIGHTS means patent rights to any subject matter falling within the scope of the claims of the patents set forth in “Appendix E –
Xenogen’s Imaging Patents” which is attached to this Agreement and made a part hereof; and any continuing applications thereof including divisions and substitutions to the extent they claim in vivo imaging as the subject matter; and any
patents or reissues issuing on said patents or continuing applications with claims which have not been found invalid or unenforceable by a court of law or agency of competent jurisdiction from which an appeal has not been or cannot be taken; any and
all of which shall be automatically incorporated and added to this Agreement and shall periodically be added to said Appendix E. 
  
 1.18 XENOGEN LICENSED METHOD means any method that is covered by XENOGEN LICENSED PATENT RIGHTS, or the use of which would constitute, but for the license granted to
PROMEGA pursuant to this Agreement, an infringement of any pending or issued claim within the XENOGEN LICENSED PATENT RIGHTS. 
  
 1.19 XENOGEN LICENSED PATENT RIGHTS means patent rights to any subject matter falling within the scope of the claims of the patents set forth in “Appendix D –
Xenogen’s Non-Imaging Patents” which is attached to this Agreement and made a part hereof; and any continuing applications thereof including divisions and substitutions but excluding claims in continuation-in-part applications to the
extent they contain claimed subject matter other than that adequately supported in the issued patents listed hereinabove; and any patents or reissues issuing on said patents or continuing 

  

 Page 4 of 29 

 
applications with claims which have not been found invalid or unenforceable by a court of law or agency of competent jurisdiction from which an appeal has
not been or cannot be taken; any and all of which shall be automatically incorporated and added to this Agreement and shall periodically be added to said Appendix D. 
  
 1.20 XENOGEN LICENSED PRODUCT means any material, product or kit that: (a) incorporates the PROMEGA LICENSED TECHNOLOGY; and at the same
time (b) either is claimed by the XENOGEN LICENSED PATENT RIGHTS, or whose manufacture, use, or sale would constitute, but for the license granted to PROMEGA pursuant to this Agreement an infringement of a VALID CLAIM within the XENOGEN LICENSED
PATENT RIGHTS. Transgenic animals are specifically excluded from the scope of this definition. 
  
 1.21 XENOGEN LICENSED SERVICE means any service, process or procedure that is intended to create a XENOGEN LICENSED PRODUCT in accordance with the request of a not-for-profit entity and either: (i) uses a XENOGEN
LICENSED PRODUCT in the course of performing such service, process or procedure or (ii) includes the use of a XENOGEN LICENSED METHOD or a method under the XENOGEN IMAGING PATENT RIGHTS in conjunction with the PROMEGA LICENSED TECHNOLOGY in the
course of performing such service, process or procedure. Specifically excluded from this definition are fee-for-service activities, including but not limited to screening of compounds for their biological and toxicological effects or any other
activities that are other than the creation of a XENOGEN LICENSED PRODUCT. 
  
 2. PROMEGA LICENSE GRANT 
  
 2.1 PROMEGA hereby grants to XENOGEN
and XENOGEN’s AFFILIATES, and XENOGEN and XENOGEN’s AFFILIATES accept, subject to the terms and conditions hereof, a non-exclusive, royalty-bearing license, in the TERRITORY under the PROMEGA LICENSED PATENT RIGHTS to use PROMEGA LICENSED
METHODS with respect to the PROMEGA LICENSED TECHNOLOGY to develop, make, have made, use, propagate, sell, have sold (only through a third party distributor), offer for sale, import and otherwise commercialize PROMEGA LICENSED PRODUCTS for the
XENOGEN FIELD OF USE during the TERM. 
  
 2.2 The grant of rights set forth in
this Article 2 (PROMEGA LICENSE GRANT) are specifically limited by the following limited use label licence which XENOGEN hereby agrees shall be legibly and prominently displayed either as is or in a form at least as restrictive on or with all
LICENSED PRODUCTS sold or as transferred to third parties by XENOGEN or its AFFILIATES: 
  
 “This product is provided under a license from Promega Corporation. Under the terms of that license the use of this product and derivatives thereof is strictly limited to that of a research reagent. No right to
use this 

  

 Page 5 of 29 

 
product for any diagnostic, therapeutic, or commercial application is hereby conveyed to the purchaser of this product.” 
  
 XENOGEN and its AFFILIATES shall also include such label license in their description of
PROMEGA LICENSED PRODUCTS in their published and electronic catalogues. 
  
 2.3
XENOGEN and XENOGEN’s AFFILIATES shall have the right to offer and perform PROMEGA LICENSED SERVICES for third parties, which PROMEGA LICENSED SERVICES shall consist of: (a) developing; and/or making PROMEGA LICENSED PRODUCTS for XENOGEN’s
or XENOGEN’s AFFILIATE’s use in the XENOGEN FIELD OF USE as a service conducted under contract to, or for the benefit of, a third party; and (b) developing and making PROMEGA LICENSED PRODUCTS under contract to, or for the benefit of, a
third party for said third party’s use in the XENOGEN FIELD OF USE. XENOGEN agrees that as a condition of the license granted herein that XENOGEN shall disclose to PROMEGA, in XENOGEN’s semi-annual reports provided under Paragraph 4.3, the
names of all third parties for whom XENOGEN and XENOGEN’s AFFILIATES have performed such services during each reporting period. 
  
 2.4 XENOGEN shall have the right to issue sublicenses to third parties, without any further right of those third parties to issue sublicenses. Such sublicenses issued to
third parties shall be subject to the terms and conditions of this Agreement (except that such sublicenses shall not have a minimum royalty obligation to PROMEGA) and shall provide for no more than the right of said third parties to import, develop,
propagate, make and use PROMEGA LICENSED PRODUCTS for the purposes of said third parties selling PROMEGA LICENSED PRODUCTS to end-users in the XENOGEN FIELD OF USE and performing PROMEGA LICENSED SERVICES, on behalf of end-user in the XENOGEN FIELD
OF USE, provided XENOGEN remains a licensee hereunder. 
  
 3. XENOGEN FEES,
ROYALTIES, AND OTHER CONSIDERATION 
  
 3.1 XENOGEN agrees to pay PROMEGA a
license issue fee of [***] within thirty (30) days after May 30, 2003. 
  
 3.2
XENOGEN shall pay to PROMEGA a royalty of [***] of NET SALES OF PROMEGA LICENSED PRODUCTS sold by XENOGEN and its AFFILIATES to end-users of said PROMEGA LICENSED PRODUCTS. Such royalty shall be payable to PROMEGA semi-annually in accordance with
Article 4 XENOGEN PAYMENTS AND REPORTS) below. 
  
 3.3 XENOGEN shall pay to
PROMEGA a royalty of [***] of NET SALES OF PROMEGA LICENSED SERVICES performed by XENOGEN and its AFFILIATES whereby PROMEGA LICENSED PRODUCTS are developed for, or used on behalf of a third party. XENOGEN’s and its AFFILIATES’ use of
PROMEGA LICENSED PRODUCTS in the performance of such PROMEGA LICENSED in the performance of such PROMEGA LICENSED SERVICES shall be subject to the payment of the [***] royalty on the NET 

 *** CONFIDENTIAL TREATMENT REQUESTED 
  

 Page 6 of 29 

 
SALES OF (such) PROMEGA LICENSED PRODUCTS. Such royalty shall be payable to PROMEGA semi-annually in accordance with Article 4 (PAYMENTS AND REPORTS) below.

  
 3.4 No royalty shall be due to PROMEGA with respect to the performance of the
PROMEGA LICENSED SERVICES by XENOGEN or its AFFILIATE on behalf of a third party or for the transfer of PROMEGA LICENSED PRODUCTS to such third party provided, however, that neither XENOGEN nor AFFILIATE receives cash consideration in return for
rendering such PROMEGA LICENSED SERVICE or for transferring said PROMEGA LICENSED PRODUCT to said third party. Notwithstanding the foregoing, the provisions of this Section 3.4, as well as Paragraph 3.4.1 and 3.4.2 shall apply where such third party
is a not-for-profit entity (e.g., an academic institution or not-for-profit research institute). In addition, should such cash consideration be received by XENONGEN or its AFFILIATE from such third party for such PROMEGA LICENSED SERVICE or PROMEGA
LICENSED PRODUCT, then a royalty shall be owed to PROMEGA calculated in accordance with the provisions of the preceding Paragraphs 3.2 and 3.3. 
  
 3.4.1 XENOGEN or its AFFILIATE shall pay to PROMEGA a non-refundable, up front annual license fee of [***] on a third party-by-third party basis for each
Transaction Period in which XENOGEN or its AFFILIATE performs the PROMEGA LICENSED SERVICES for no consideration as set forth in the preceding Paragraph 3.4. Said fee shall be paid within thirty (30) days of the first day of the Transaction Period
to which it pertains. A “Transaction Period” shall be a one (1) year tem from the date on which XENOGEN or its AFFILIATE first performed a PROMEGA LICENSED SERVICE for such third party under the terms of the relevant agreement, and may be
renewed for additional one (1) year terms of the payment in each subsequent year of an additional non-refundable [***] license fee on or before the date of expiration of the current Transaction Period. 
  
 3.4.2 XENOGEN and its AFFILIATES shall pay to PROMEGA the [***] royalty on
NET SALES OF PROMEGA LICENSED PRODUCTS set forth in Paragraph 3.2 with respect to PROMEGA LICENSED PRODUCTS that result from the foregoing PROMEGA LICENSED SERVICES that are governed by this Section 3.4. However, the foregoing royalties shall be
creditable against each [***] annual license fee paid to PROMEGA under Paragraph 3.4.1 for a three (3) year period from the date on which each such fee was due and payable by XENOGEN to PROMEGA. For clarity, such crediting of royalties against each
annual license fee shall pertain exclusively to those royalties resulting from the NET SALES OF PROMEGA PRODUCTS sold by XENOGEN or its AFFILIATE to the specific third party for whom said fee was paid and provided that said PROMEGA LICENSED PRODUCT
resulted from the PROMEGA LICENSED SERVICES rendered in the Transaction Period to which said fee pertains. Accordingly, the royalties of this Paragraph 3.4.2 are creditable against nothing other than the annual 

 *** CONFIDENTIAL TREATMENT REQUESTED 
  

 Page 7 of 29 

 
license fees of this Paragraph 3.4.2. They are not creditable against the Minimum Annual Royalty provided under Paragraph 3.5. 
  
 3.5 A non-refundable, non-cancellable, Minimum Annual Royalty shall be due and payable by
XENOGEN to PROMEGA in accordance with the following schedule: 
  

	 	(a)	[***] shall be paid within the thirty (30) days following May 30, 2003, and thirty (30) days after each subsequent anniversary of the EFFECTIVE DATE up to and including the fifth
such anniversary; 

  

	 	(b)	[***] shall be paid within thirty (30) days following the sixth anniversary of the EFFECTIVE DATE, and of each subsequent anniversary of the EFFECTIVE DATE up to and including the
tenth such anniversary; and, 

  

	 	(c)	[***] shall be paid within thirty (30) days following the eleventh anniversary of the EFFECTIVE DATE, and of each subsequent anniversary of the EFFECTIVE DATE

  
 during the time that this Agreement is in force. Royalties owed
by XENOGEN to PROMEGA in an Agreement Year may only be credited against the Minimum Annual Royalty due and payable by XENOGEN to PROMEGA in that same Agreement Year. Each Agreement Year shall consist of the span of one year from the EFFECTIVE DATE
until the first anniversary of the Agreement and similarly for each subsequent year until the following anniversary thereafter. No royalties other than those derived pursuant to Paragraphs 3.2 and 3.3 from XENOGEN’s and AFFILIATES’ NET
SALES OF LICENSED PRODUCTS and NET SALES OF LICENSED SERVICES may be credited against the Minimum Annual Royalty of this Paragraph 3.5. 
  
 3.6 Sublicenses issued to third parties by XENOGEN will be subject to no less than the obligations, royalties and fees provided in this Agreement (expect that such
sublicenses shall not have the minimum royalty obligation set forth in Paragraph 3.5 herein to PROMEGA). XENOGEN shall be responsible for passing through to PROMEGA in each reporting period provided under Paragraph 4.1 herein all of such
sublicensees’ payments of the royalties and fees (including, without limitation, the license issue fee for each such sublicensee as set forth in Paragraph 3.1) in the amounts, percentages and manner set forth in this Agreement. 
  
 3.7 The obligation of XENOGEN to pay royalties under this Article 3 (FEES, ROYALTIES AND
OTHER CONSIDERATION—XENOGEN) shall continue on a country-by-country and VALID CLAIM-by-VALID CLAIM basis for each PROMEGA LICENSED PRODUCT and each PROMEGA LICENSED SERVICE until such time as neither the manufacture, sale, offer for sale,
importation nor use of such PROMEGA LICENSED PRODUCT or PROMEGA LICENSED SERVICE would infringe a VALID CLAIM in such country. 
  
 3.8 In the event that XENOGEN or its AFFILIATE authorizes a third party agent solely to breed and/or propagate and maintain PROMEGA LICENSED PRODUCTS for 

 *** CONFIDENTIAL TREATMENT REQUESTED 
  

 Page 8 of 29 

 
transfer to fourth parties but does not transfer title to such PROMEGA LICENSED PRODUCTS to such third party agent, then no royalties shall be due on account
of such breeding and/or propagation, but a [***] royalty shall be due on amounts received resulting from the NET SALES of PROMEGA LICENSED PRODUCTS to end-users. 
  
 3.9 Neither XENOGEN nor its AFFILIATES shall owe any amounts for XENOGEN’s and its AFFILIATES’ use of PROMEGA LICENSED PRODUCTS or
performance of PROMEGA LICENSED SERVICES for their own internal research and development purposes provided that such research is not paid for with money by a third party other than the U.S. Government. 
  
 3.10 XENOGEN shall be wholly responsible for the compliance with the terms and conditions of
this Agreement by XENOGEN’s AFFILIATES and XENOGEN’s sublicensees. Such responsibility includes, but is not limited to, the timely payment of royalties and the filing of reports to PROMEGA as set forth elsewhere herein. Any omission of
performance or contravening act with respect to this Agreement by XENOGEN’s AFFILIATE or any sublicensee hereunder shall be construed as an omission of performance or contravening act on the part of XENOGEN. 
  
 3.11 In consideration of any sublicenses issued by XENOGEN granting rights which fall within
the scope of the rights granted herein and which were issued prior to the EFFECTIVE DATE and in further consideration of PROMEGA’s covenant not to sue set forth in Paragraph 11.5 below, XENOGEN need not pay to PROMEGA any additional amounts.
Such consideration for such sub-licensing is non-refundable, non-cancelable and not an advance payment against any other payment. Further, such consideration is predicated upon XENOGEN’s warranty set forth in Paragraph 11.6 below. In the event
that the sublicense issue fees due from XENOGEN’s sublicenses issued prior to the EFFECTIVE DATE are shown to exceed [***] [calculated as the number of sublicenses issued multiplied by [***], the entire sum of the overage shall be subject to
the late fee assessment set forth in Paragraph 4.7. 
  
 3.12 In consideration of
any use of the technology, services and products by XENOGEN, its AFFILIATES, or XENOGEN’s sublicensees, which falls within the scope of the rights granted herein and which occurred prior to the EFFECTIVE DATE, and in further consideration of
PROMEGA’s covenant not to sue set forth in Paragraph 11.5 below, XENOGEN shall pay to PROMEGA [***] within fifteen (15) days the full execution of this Agreement by the parties hereto. Such consideration for possible prior use is
non-refundable, non-cancelable and not an advance against any other payment. Further, such consideration is predicated upon XENOGEN’s warranty as set forth in Paragraph 11.7 below. In the event that XENOGEN’s, its AFFILIATES’ and
XENOGEN’s sublicensees’ NET SALES of LICENSED PRODUCTS prior to the EFFECTIVE DATE are shown to exceed [***] 

 *** CONFIDENTIAL TREATMENT REQUESTED 
  

 Page 9 of 29 

 
[***] the entire sum of the overage shall be subject to the royalty set forth in Paragraph 3.2 and the late fee assessment set forth in Paragraph 4.7.

  
 4. PAYMENTS AND REPORTS 
  
 4.1 Each party shall make semi-annual royalty reports to the other party hereunder on or
before February 28 and August 31 of each year during the TERM. Each such royalty report will show respectively for each of XENOGEN, its AFFILIATES and XENOGEN’s sublicensees, and PROMEGA and its AFFILIATES: 
  

	 	(a)	The invoice amounts and NET SALES OF PROMEGA LICENSED PRODUCTS or NET SALES OF XENOGEN LICENSED PRODUCTS, as the case may be, sold during the most recently completed calendar half
year; 

  

	 	(b)	the number of each type of PROMEGA LICENSED PRODUCT or XENOGEN LICENSED PRODUCT, as the case may be, sold; 

  

	 	(c)	the royalties, in U.S. dollars, payable hereunder with respect to such sales of PROMEGA LICENSED PRODUCTS or XENOGEN LICENSED PRODUCTS, as the case may be; 

 

	 	(d)	the royalties, in U.S. dollars, payable hereunder with respect to the NET SALES OF PROMEGA LICENSED SERVICES or NET SALES OF XENOGEN LICENSED SERVICES, as the case may be;

  

	 	(e)	the method used to calculate the royalty owed by XENOGEN to PROMEGA or by PROMEGA to XENOGEN, as the case may be, in each category (a) through (d) set forth in this Paragraph 4.1.

  

	 	(f)	an accounting of: (i) the respective annual license fees set forth in Paragraph 3.4.1 listing customers and addresses and the dollar amounts; and, (ii) the sum of the royalties
credited against said respective annual license fees as provided in Paragraph 3.4.2. 

  

	 	(g)	the name and address of each entity issued a sublicense by XENOGEN during the reporting period, and any such sub-licensee not previously thus identified. 

 
 4.2 If no sales of PROMEGA LICENSED PRODUCTS or XENOGEN LICENSED PRODUCTS, as the case may
be, have been made during any reporting period, a statement to this effect shall be required. 
  
 4.3 Each party’s royalty reports under Section 4.1 shall contain the names of any and all third parties for whom such party, its AFFILIATES, and XENOGEN’s sublicensees respectively have performed PROMEGA
LICENSED SERVICES or XENOGEN LICENSED SERVICES, as the case may be, during the most recently completed calendar half year as set forth under this Agreement. Each party’s first such royalty report shall further contain all information required
under this Paragraph 4.3 regarding any and all PROMEGA LICENSED SERVICES or XENOGEN LICENSED SERVICES, as the case may be, performed prior to the EFFECTIVE DATE. 

 *** CONFIDENTIAL TREATMENT REQUESTED 
  

 Page 10 of 29 

 4.4 Each royalty report under this Article 4 (PAYMENTS AND REPORTS) shall be accompanied by that party’s payment of
royalties and sublicense issues fees and sublicensees’ royalties to the other party. All payments due hereunder shall be payable in United States Dollars. Conversion of foreign currency to U.S. Dollars shall be made at the conversion rate
existing in the United States as reported in the Wall Street Journal on the last working day of each royalty reporting period. 
  
 4.5 Each party hereto shall maintain at its principal office usual books of account and records showing its actions under this Agreement. Such books and records shall be
open to inspection and copying, upon reasonable notice during usual business hours by an independent certified public accountant retained by one party hereunder and reasonably acceptable to the other party for three (3) years after the calendar half
year to which they pertain, for purposes of verifying the accuracy of the royalties paid under this Agreement by the party being inspected. The fees and expenses of a party’s representatives performing such examination shall be borne by such
party. However, if an error in the reporting of expenses or proceeds of more than ten percent (10%) for any calendar semi-annual reporting period is discovered, then the fees and expenses of these representatives shall be borne by the other party.
Each party hereunder and any such independent certified public accountant shall treat the other party’s books and records as confidential. 
  
 4.6 PROMEGA shall have the right for the period of two (2) years following the EFFECTIVE DATE to inspect XENOGEN’s books and records in the manner set forth in
Paragraph 4.5 for the purpose of verifying: 
  

	 	(a)	XENOGEN’s sublicensing activities prior to the EFFECTIVE DATE as set forth in Paragraphs 3.11 and 11.6 herein; and, 

  

	 	(b)	XENOGEN’s, its AFFILIATES’, and XENOGEN’s sublicensees’ NET SALES OF PROMEGA LICENSED PRODUCTS and NET SALES OF PROMEGA LICENSED SERVICES prior to the EFFECTIVE
DATE as provided under Paragraphs 3.12 and 11.7 herein. 

  
 4.7 In
the event that payments made by one party hereunder to the other party are late, such party shall pay to the other party interest charges at a rate of one percent (1.0%) per month. Such interest will be calculated from the date payment was due until
actually received by such other party. 
  
 5. XENOGEN LICENSE GRANT

  
 5.1 XENOGEN hereby grants to PROMEGA and PROMEGA’s AFFILIATES, and
PROMEGA and PROMEGA’s AFFILIATES accept, subject to the terms and conditions hereof, a non-exclusive, non-sublicenseable, royalty-bearing license in the TERRITORY under the XENOGEN LICENSED PATENT RIGHTS and the XENOGEN IMAGING PATENT RIGHTS to
use XENOGEN LICENSED METHODS and the methods of the XENOGEN IMAGING PATENT RIGHTS to develop, make, have made, use, propagate, sell, have sold (only through a third party distributor), offer for sale, import and otherwise commercialize XENOGEN
LICENSED PRODUCTS for the PROMEGA FIELD OF 

  

 Page 11 of 29 

 
USE during the TERM. The parties agree that the foregoing license under the XENOGEN IMAGING PATENT RIGHTS does not include PROMEGA’s own: (i)
preclinical drug development studies, such as the screening of drugs or compounds and toxicology testing, and (ii) development of transgenic animal models of disease. 
  
 5.2 Specifically, the grant of rights to PROMEGA by XENOGEN in Paragraph 5.1 above includes, but is not limited to: 
  

	 	(i)	a right of PROMEGA under the XENOGEN LICENSED PATENT RIGHTS and the XENOGEN IMAGING PATENT RIGHTS to use the XENOGEN LICENSED METHODS and the methods of the XENOGEN IMAGING PATENT
RIGHTS in PROMEGA’s own internal research for the development of XENOGEN LICENSED PRODUCTS for research applications in the PROMEGA FIELD OF USE; 

  

	 	(ii)	a right of PROMEGA under the XENOGEN LICENSED PATENT RIGHTS and the XENOGEN IMAGING PATENT RIGHTS to use the XENOGEN LICENSED METHODS and the methods of the XENOGEN IMAGING PATENT
RIGHTS in PROMEGA’s manufacture, use, advertising, importation and sale of XENOGEN LICENSED PRODUCTS for research applications in the PROMEGA FIELD OF USE; 

  

	 	(iii)	a right of PROMEGA to perform XENOGEN LICENSED SERVICES for third parties that are not-for-profit entities (e.g., an academic institution or not-for-profit research institute) to
develop XENOGEN LICENSED PRODUCTS for use under the PROMEGA FIELD OF USE; and, 

  

	 	(iv)	a non-transferable, non-sublicenseable right of PROMEGA’s customers who purchase XENOGEN LICENSED PRODUCTS from PROMEGA to receive a license to practice the XENOGEN IMAGING
PATENT RIGHTS with such XENOGEN LICENSED PRODUCTS in the PROMEGA FIELD OF USE. 

  
 5.3 PROMEGA shall have no right to issue sub-licenses hereunder with respect to the XENOGEN LICENSED PATENT RIGHTS. 
  
 5.4 The grant or rights set forth in this Article 5 (XENOGEN LICENSE GRANT) are specifically limited by the following limited use label license and notice of patent
rights that PROMEGA hereby agrees shall be legibly and prominently displayed either as is or in a form at least as restrictive on or with all XENOGEN LICENSED PRODUCTS sold or transferred to third parties by PROMEGA or its AFFILIATES: 
  
 “Whenever this product is used for in vivo imaging in animals, such use
is covered by a license from Xenogen Corporation. Under the terms of that license the use of this product and derivatives thereof is strictly limited to that of a research reagent by researchers at not-for profit entities (e.g. academic institutions
and not-for-profit research institutes). All other use is strictly prohibited. No right to use this product for any diagnostic, therapeutic, or commercial application is hereby conveyed to the purchaser of this product. Detection of light emitted
from within animals is covered 

  

 Page 12 of 29 

 
by one or more patents controlled by Xenogen Corporation, including but not limited to U.S. Patent Nos. 6,217,847 and 5,650,135, and the purchase or transfer
of this product is not intended, either expressly or by implication, to grant any right or license to practice under any such patents except as set forth above herein. Purchasers are advised to contact Xenogen Corporation, 860 Atlantic Avenue,
Alameda, California 94501 for information regarding a license to practice under such patents.” 
  
 PROMEGA and its AFFILIATES shall also include such label license and patent notice in their description of XENOGEN LICENSED PRODUCTS in their published and electronic catalogues. 
  
 5.5 PROMEGA and PROMEGA’s AFFILIATES shall have the right to offer and perform XENOGEN
LICENSED SERVICES in the PROMEGA FIELD OF USE for third parties that are not-for-profit entities (e.g., an academic institution or not-for-profit research institute), which XENOGEN LICENSED SERVICES shall consist of: (a) developing and/or making
XENOGEN LICENSED PRODUCTS for PROMEGA’s or PROMEGA’s AFFILIATE’S use in the PROMEGA FIELD OF USE as a service conducted under contract to, or for the benefit of, a third party; and (b) developing and making XENOGEN LICENSED PRODUCTS
under contract to, or for the benefit of, a third party for said third party’s use in the PROMEGA FIELD OF USE. 
  
 6. PROMEGA FEES, ROYALTIES, AND OTHER CONSIDERATION 
  
 6.1 PROMEGA shall pay to XENOGEN a royalty of [***] of NET SALES OF XENOGEN LICENSED PRODUCTS sold by PROMEGA and its AFFILIATES to end-users of said XENOGEN LICENSED
PRODUCTS. Such royalty shall be payable to XENOGEN semi-annually in accordance with Paragraph 4.1 above. 
  
 6.2 PROMEGA shall pay to XENOGEN a royalty of [***] of NET SALES OF XENOGEN LICENSED SERVICES performed by PROMEGA and its AFFILIATES whereby XENOGEN LICENSED PRODUCTS are developed for, or used on behalf of, a third
party. PROMEGA’s and its AFFILIATES’ use of XENOGEN LICENSED PRODUCTS in the performance of such XENOGEN LICENSED SERVICES shall be subject to the payment of the [***] royalty on the NET SALES OF (such) XENOGEN LICENSED PRODUCTS. Such
royalty shall be payable to XENOGEN semi-annually in accordance with Paragraph 4.1 above. 
  
 6.3 No royalty shall be due to XENOGEN with respect to the performance of the XENOGEN LICENSED SERVICES by PROMEGA or its AFFILIATE on behalf of a third party or for the transfer of XENOGEN LICENSED PRODUCTS to a
third party by PROMEGA or its AFFILIATE provided, however, that neither PROMEGA nor its AFFILIATE receives cash consideration in return for rendering such XENOGEN LICENSED SERVICE or for transferring said XENOGEN LICENSED PRODUCT to said third
party. In addition, should such cash consideration be received by PROMEGA 

 *** CONFIDENTIAL
TREATMENT REQUESTED 
  

 Page 13 of 29 

 
or its AFFILIATE from such third party for such XENOGEN LICENSED SERVICE or XENOGEN LICENSED PRODUCT, then a royalty shall be owed to XENOGEN calculated in
accordance with the provisions of the preceding Paragraphs 6.1 and 6.2. 
  
 6.4
The obligation of PROMEGA to pay royalties under Paragraphs 6.1 and 6.2 shall continue on a country-by-country and VALID CLAIM-by-VALID CLAIM basis for each XENOGEN LICENSED PRODUCT and each XENOGEN LICENSED SERVICE until such time as neither the
manufacture, sale, offer for sale, importation nor use of such XENOGEN LICENSED PRODUCT or XENOGEN LICENSED SERVICE would infringe a VALID CLAIM in such country. 
  
 6.5 Neither PROMEGA nor its AFFILIATES shall owe any amounts for PROMEGA’s and its AFFILIATES’ use of XENOGEN LICENSED PRODUCTS or
performance of XENOGEN LICENSED SERVICES for their own internal research and development purposes provided that such research is not paid for with money by a third party other than the U.S. Government. 
  
 6.6 PROMEGA shall be wholly responsible for the compliance with the terms and conditions of
this Agreement by PROMEGA’s AFFILIATES. Such responsibility includes, but is not limited to, the timely payment of royalties and the filing of reports to XENOGEN as set forth elsewhere herein. Any omission of performance or contravening act
with respect to this Agreement by PROMEGA’s AFFILIATE shall be construed as an omission of performance or contravening act on the part of PROMEGA. 
  
 7. PRODUCT MARKING 
  
 7.1 The Parties agree to mark all PROMEGA LICENSED PRODUCTS and XENOGEN LICENSED PRODUCTS used or sold under the terms of this Agreement, their containers or package inserts, in accordance with applicable patent
marking laws. 
  
 7.2 XENOGEN agrees to mark all PROMEGA LICENSED PRODUCTS used or
sold under the terms of this Agreement, their containers or package inserts, with the label license statement set forth under Paragraph 2.2 herein. 
  
 7.3 PROMEGA agrees to mark all XENOGEN LICENSED PRODUCTS used or sold under the terms of this Agreement, their containers or package inserts, with the label license
statement set forth under Paragraph 5.4 herein. 
  
 8. INFRINGEMENT

  
 8.1 In the event that a Party shall learn of the substantial infringement
of any patent sublicensed under this Agreement, the other Party shall promptly notify such Party in writing. 
  
 8.2 PROMEGA is under no obligation whatsoever to enforce its rights under the PROMEGA LICENSED PATENT RIGHTS and nor is XENOGEN under any obligation 

  

 Page 14 of 29 

 
whatsoever to enforce its rights under the XENOGEN LICENSED PATENT RIGHTS or XENOGEN IMAGING PATENT RIGHTS. 
  
 9. LIFE OF THE AGREEMENT 
  
 9.1 Unless otherwise terminated by an operation of law or by acts of the Parties in
accordance with the terms of this Agreement, this Agreement shall be in force during the TERM. 
  
 9.2 This Agreement and the license granted under it may be terminated by either Party: (i) upon ninety (90) days written notice to the other Party for such Party’s material breach of this Agreement and failure to
cure in accordance with Article 10 (BREACH AND CURE); or (ii) should either Party, become insolvent, file a petition under any bankruptcy or insolvency act, or have any such petition filed against it, or offer any general composition to its
creditors, because of the happening of such act, event or offer. In addition, either Party may terminate its license and attendant obligations hereunder without cause upon ninety (90) days written notice to the other Party; provided that such
termination will not terminate the other Party’s license and attendant obligations hereunder. 
  
 9.3 Upon any termination of this Agreement and any license granted under it, for any reason other than a failure by a Party to cure a material breach of the Agreement within the ninety (90) day period permitted under
Paragraphs 9.2 and 10.2, the Parties, their AFFILIATES and their sublicensees shall have the right for one hundred and twenty (120) days to dispose of all previously made or substantially completed PROMEGA LICENSED PRODUCTS OR XENOGEN LICENSED
PRODUCTS, as the case may be, and to complete all agreements and orders for such PROMEGA LICENSED PRODUCTS and PROMEGA LICENSED SERVICES or XENOGEN LICENSED PRODUCTS and XENOGEN LICENSED SERVICES, as the case may be, then on hand, provided however,
that the sale of such PROMEGA LICENSED PRODUCTS and PROMEGA LICENSED SERVICES or XENOGEN LICENSED PRODUCTS and XENOGEN LICENSED SERVICES, as the case may be, shall be subject to the terms of this Agreement including, but not limited to, the payment
of royalties at the rate and the time provided herein and the rendering of reports thereon. 
  
 9.4 Expiration or termination of this Agreement for any reason shall not relieve XENOGEN of its obligation hereunder to make all payments to PROMEGA pertaining to: (i) XENOGEN’s license issue fee; (ii) royalties
resulting from XENOGEN’s and XENOGEN’s AFFILIATE’S NET SALES of PROMEGA LICENSED PRODUCTS; and, (iii) pass-through of the sublicense issue fees resulting from XENOGEN’s sublicensing activities, and royalties resulting from
XENOGEN’s sublicensees’ NET SALES OF PROMEGA LICENSED PRODUCTS and NET SALES OF PROMEGA LICENSED SERVICES that have accrued during the time the Agreement was in force. Similarly, expiration or termination of this Agreement for any reason
shall not relieve PROMEGA of its obligation hereunder to make all payments to XENOGEN pertaining to PROMEGA’s and AFFILIATES’ royalties resulting from PROMEGA’s and 

  

 Page 15 of 29 

 
PROMEGA’s AFFILIATES’ NET SALES OF XENOGEN LICENSED PRODUCTS and NET SALES OF XENOGEN LICENSED SERVICES that have accrued during the time the
Agreement was in force. 
  
 9.5 Expiration or termination of this Agreement for
any reason shall not relieve either party hereto of its obligation hereunder to make all royalty payments accrued pursuant to Articles 3 or 6 herein. 
  
 9.6 In the event of the termination of this Agreement, XENOGEN may assign to PROMEGA all sublicenses to the PROMEGA LICENSED PATENT RIGHTS and PROMEGA LICENSED TECHNOLOGY
which are consistent with the rights and obligations due PROMEGA hereunder, which sublicenses shall survive provided that each sublicensee complies with all the terms and conditions of this Agreement. However, if termination occurs as the result of
XENOGEN’s material breach of this Agreement as provided under Paragraph 9.2, PROMEGA at its sole discretion, shall determine whether any or all of the sublicenses issued by XENOGEN pursuant to this Agreement shall be cancelled or assigned to
PROMEGA. 
  
 9.7 Upon termination of this Agreement, the following provisions
shall survive the termination of this Agreement: 4 (PAYMENTS AND REPORTS), 9 (LIFE OF THE AGREEMENT), 11 (LIMITED WARRANTY AND COVENANT), 12 (COMPLIANCE WITH GOVERNMENTAL OBLIGATIONS), 14 (NOTICE), 15 (CONFIDENTIALITY), 17 (INDEMNIFICATION) and 18
(MISCELLANEOUS) herein. 
  
 10. BREACH AND CURE 
  
 10.1 In addition to applicable legal standards, either of XENOGEN or PROMEGA shall be in
material breach of this Agreement for its failure to pay royalties pursuant to Article 3 or Article 6, respectively. 
  
 10.2 Either Party shall have the right to cure its material breach within a reasonable time, during which period this Agreement cannot be terminated on account of such
breach, but in no event later than ninety (90) days after receiving written notice and identification of such breach from the non-breaching Party. 
  
 11. LIMITED WARRANTY AND COVENANT 
  
 11.1 Each of the Parties represents and warrants that: (i) it has the lawful right to grant its respective license and sublicense hereunder; (ii) as of the EFFECTIVE
DATE, it has not received from a third party notice that the manufacture, sale or use of a LICENSED PRODUCT or LICENSED METHOD within the applicable FIELD OF USE would infringe any intellectual property rights of such third party; (iii) except for
U.S. Patent Nos. 5,583,024, 5,674,713 and 5,700,673 assigned to the Regents of the University of California, it owns or has rights to the applicable LICENSED PATENT RIGHTS and LICENSED TECHNOLOGY such that it can grant the other party the rights and
licenses stated herein; and (iv) other than the amounts payable by XENOGEN under Article 3 

  

 Page 16 of 29 

 
(XENOGEN FEES, ROYALTIES AND OTHER CONSIDERATION) and under any separate agreement pertaining to XENOGEN’s proposed commercialization of PROMEGA
LICENSED PRODUCTS falling within the scope of at least one valid claim occurring within issued U.S. Patent Nos. 5,583,024, 5,674,713 and 5,700,673 assigned to the Regents of the University of California, XENOGEN will not owe any royalties or other
amounts to any third party from which PROMEGA licensed any of the PROMEGA LICENSED PATENT RIGHTS. 
  
 11.2 The licenses granted herein to the PROMEGA LICENSED TECHNOLOGY, PROMEGA LICENSED PATENT RIGHTS and XENOGEN PATENT RIGHTS are provided WITHOUT WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR ANY
OTHER WARRANTY, EXPRESS OR IMPLIED. THE PARTIES MAKE NO REPRESENTATION OR WARRANTY THAT THE PROMEGA LICENSED PRODUCTS, XENOGEN LICENSED PRODUCTS, XENOGEN LICENSED METHOD OR PROMEGA LICENSED METHOD WILL NOT INFRINGE ANY PATENT OR OTHER PROPRIETARY
RIGHT OF THIRD PARTIES. 
  
 11.3 IN NO EVENT WILL EITHER PARTY BE LIABLE TO THE
OTHER PARTY FOR ANY INCIDENTAL, SPECIAL OR CONSEQUENTIAL DAMAGES RESULTING FROM EXERCISE OF ITS RIGHTS UNDER THIS AGREEMENT OR THE USE OF PROMEGA LICENSED PRODUCT, PROMEGA LICENSED SERVICE, XENOGEN LICENSED PRODUCT, OR XENOGEN LICENSED SERVICE.

  
 11.4 Nothing in this Agreement shall be construed as: 
  

	 	(a)	a warranty or representation by either Party as to the validity or scope of the PROMEGA LICENSED PATENT RIGHTS, XENOGEN IMAGING PATENT RIGHTS or XENOGEN LICENSED PATENT RIGHTS,
respectively; or 

  

	 	(b)	a warranty or representation that anything made, used, sold or otherwise disposed of under any sublicense or cross-sublicense granted in this Agreement is or will be free from
infringement of patents of third parties; or 

  

	 	(c)	an obligation to bring or prosecute actions or suits against third parties for patent infringement except as provided in Article 8 (INFRINGEMENT); or 

  

	 	(d)	conferring upon either Party by implication, estoppel or otherwise any license or rights under any patents of the other Party other than the PROMEGA LICENSED PATENT RIGHTS, XENOGEN
IMAGING PATENT RIGHTS and XENOGEN PATENT RIGHTS, respectively, as defined herein, regardless of whether such patents are dominant or subordinate to the PROMEGA LICENSED PATENT RIGHTS, XENOGEN IMAGING PATENT RIGHTS or XENOGEN LICENSED PATENT RIGHTS,
respectively; or 

  

	 	(e)	 an obligation by PROMEGA to furnish know-how other than that provided in the PROMEGA LICENSED PATENT RIGHTS or by 

  

 Page 17 of 29 

	 	 
XENOGEN to furnish know-how other than that provided in the XENOGEN LICENSED PATENT RIGHTS. 

  
 11.5 In consideration for the payment received under Paragraphs 3.11 and 3.12, and except
with respect to the obligations created by, acknowledged, or arising out of this Agreement, PROMEGA does hereby for itself and its legal successor and assigns and licensors, unconditionally releases and covenants not to sue, and absolutely and
forever discharges XENOGEN and its shareholders, officers, directors, employees, agents, attorneys, legal successor and assigns, of and from any and all claims, demands, damages, debts, liabilities, accounts reckoning, obligations, costs, expenses,
liens, actions and causes of action of every kind and nature whatsoever, whether now known or unknown, suspected or unsuspected, matured or unmatured, arising out of, or relating to, XENOGEN’s use or practice of the PROMEGA LICENSED PATENT
RIGHTS and PROMEGA LICENSED TECHNOLOGY occurring prior to the EFFECTIVE DATE and releases XENOGEN from any and all claims PROMEGA or its licensor may have against XENOGEN arising out of, or relating to, such use or practice by XENOGEN; provided that
XENOGEN’s warranties set forth in Paragraphs 11.6 and 11.7 below are not shown to be in error. 
  
 11.6 XENOGEN warrants that prior to the EFFECTIVE DATE, XENOGEN issued no sublicenses falling within the scope of this Agreement and its computation of the sum of sublicense issue fees set forth in Paragraph 3.11
predicated upon the combination of XENOGEN’s sublicensing of the technology, services and products which falls within the scope of the rights granted herein and occurring prior to the EFFECTIVE DATE does not exceed a total of [***]. 

 
 11.7 XENOGEN warrants that its computation of NET SALES OF PROMEGA LICENSED PRODUCTS and
NET SALES OF PROMEGA LICENSED SERVICES set forth in Paragraph 3.12 predicated upon the combination of XENOGEN’s, its AFFILIATES’ and XENOGEN’s sublicensees’ use of the technology, services and products which falls within the
scope of the rights granted herein and occurring prior to the EFFECTIVE DATE does not exceed a total of [***]. 
  
 12. COMPLIANCE WITH GOVERNMENTAL OBLIGATIONS 
  
 The Parties shall comply with all governmental requests directed to it relating to this Agreement and will provide all information and assistance necessary to comply with such governmental requests. Failure to take necessary action and to
comply with said requests shall be considered a material breach of this Agreement. the Parties disclaim any obligations or liabilities arising under the license provisions of this Agreement if the other Party is charged in a governmental action for
not complying with or fails to comply with any governmental regulations relating to this Agreement. 

 *** CONFIDENTIAL TREATMENT REQUESTED 
  

 Page 18 of 29 

 13. PUBLICITY 
  
 13.1 All public announcements regarding the existence or terms of this Agreement shall be coordinated between PROMEGA and XENOGEN and shall be made only by mutual written
agreement, and each Party agrees that its agreement shall not be unreasonably withheld or delayed. Nevertheless, either Party may make public any statement relating to the existence or terms of this Agreement (a “Written Disclosure”) it
believes in good faith, based upon the advice of counsel, is required by applicable law, rule or regulation or any listing or trading agreement concerning its or its AFFILIATES’ publicly traded securities; provided, however, that such Written
Disclosure shall minimize to the extent possible the financial information disclosed, and that prior to making such Written Disclosure, the disclosing Party shall provide to the other Party a copy of the materials proposed to be disclosed and
provide the receiving Party with an opportunity to promptly review the Written Disclosure. 
  
 13.2 Except as expressly stated in Article 7 (PRODUCT MARKING), nothing contained in this Agreement shall be construed as conferring any right to use in advertising, publicity, or other promotional activities any
name, trade name, trademark, or other designation of the Parties. 
  
 14.
NOTICE 
  
 Any notices given under this Agreement shall be in writing and
sent to the respective Party at such Party’s address as follows: 
  

			
	 if to PROMEGA, to:
	  	Attention: General Counsel
	 	  	Promega Corporation
	 	  	2800 Woods Hollow Road
	 	  	Madison, Wisconsin 53711-5399
	 	  	Fax: (608) 277-2660
	 	  	 
	 if to XENOGEN, to:
	  	Attention: President
	 	  	Xenogen Corporation
	 	  	860 Atlantic Avenue
	 	  	Alameda, California 94501
	 	  	Fax: (510) 291-6196
	 	  	 
	 With a copy to:
	  	Attention: Legal Department
	 	  	Xenogen Corporation
	 	  	860 Atlantic Avenue
	 	  	Alameda, California 94501
	 	  	Fax: (510) 291-6196

  
 Any notice shall be deemed to have
been given (i) when delivered in person, (ii) one business day after deposit with a nationally recognized overnight courier service, (iii) five (5) business days after being deposited in the United States mail postage prepaid, first class,
registered or certified mail or (iv) the business day on which it is sent and received by facsimile transmission. 
  

 Page 19 of 29 

 15. CONFIDENTIALITY 
  
 15.1 Each Party may, but is not obligated to, receive confidential information from the other Party. Each Party shall not disclose, or otherwise make available to any
third party, confidential information received from the other Party without the prior written permission of the disclosing party; provided, however, that the obligations of confidentiality hereunder shall apply only to information which has been
designated in writing as “confidential” or, if orally disclosed, designated as “confidential.” Further, the obligations of confidentiality hereunder shall not apply to any information which can be demonstrated by competent
written evidence to: 
  

	 	(i)	have been known to the receiving Party prior to receipt thereof from the disclosing Party; 

  

	 	(ii)	have been or have become a matter of public information or publicly available through no act or failure to act on the part of the receiving Party; 

  

	 	(iii)	have been acquired by the receiving Party from a third party entitled to disclose the information to it; or 

  

	 	(iv)	have been independently developed by the receiving Party without reference to or use of such confidential information, as demonstrated by written records. 

 
 15.2 Notwithstanding the provisions of Paragraph 15.1 above, each Party may disclose the
other Party’s Confidential Information to the extent such disclosure is reasonably necessary to exercise the rights granted to it, or reserved by it, under this Agreement (including prosecuting or defending litigation, complying with applicable
governmental regulations, or submitting information to tax or other governmental authorities); provided that if a Party is required to make any such disclosure of the other Party’s Confidential Information, to the extent it may legally do so,
it will give reasonable advance written notice to the latter Party of such disclosure and, save to the extent inappropriate in the case of patent applications or otherwise, will use its reasonable efforts to secure confidential treatment of such
information prior to its disclosure (whether through protective orders or otherwise). In addition, either Party may disclose the terms, or provide copies, of this Agreement to existing or potential investors or acquirers or merger partners, or to
professional advisors (e.g., attorneys, accountants and prospective investment bankers) involved in such activities, for the limited purpose of evaluating such investment or transaction and under appropriate conditions of confidentiality.

  
 16. FORCE MAJEURE 
  
 The Parties shall be excused from any performance required hereunder if such performance is
rendered impossible or unfeasible due to any catastrophes or other major events beyond their reasonable control, including, without limitation, war, riot, and insurrection; acts of terrorism; laws, proclamations, edicts, ordinances or regulations;
strikes, lock-outs or other serious labor disputes; and floods, fires, explosions, or other 

  

 Page 20 of 29 

 
natural disaster. When such events have abated, the Parties’ respective obligations hereunder shall resume. 
  
 17. INDEMNIFICATION 
  
 17.1 XENOGEN and its AFFILIATES agree to indemnify, hold harmless and defend PROMEGA and its officers, employees and agents; and the
inventors of patents and patent applications in the PROMEGA LICENSED PATENT RIGHTS and their employers (collectively, the “Promega Indemnitees”), against any and all claims, suits, losses, damage, costs, fees, and expenses (collectively,
the “Claims”) by a third party resulting from or arising out of exercise of the license under Article 2 by XENOGEN or its AFFILIATES, except in all cases to the extent such Claims result from (i) the gross negligence or intentional
misconduct of a Promega Indemnitee; or (ii) the Claim is one for which PROMEGA is obligated to provide indemnification under Paragraphs 17.2 or 17.4 below. This indemnification will include, but will not be limited to, any product liability arising
on account of XENOGEN’s, its AFFILIATES’, its or their customers’ or its sublicensees’ use of PROMEGA LICENSED PRODUCTS. 
  
 17.2 PROMEGA and its AFFILIATES agree to indemnify, hold harmless and defend XENOGEN and its officers, employees and agents; and the inventors of patents and patent
applications in the XENOGEN LICENSED PATENT RIGHTS and XENOGEN IMAGING PATENT RIGHTS and their employers (collectively, the “Xenogen Indemnitees”), against any and all claims, suits, losses, damage, costs, fees, and expenses (collectively,
the “Claims”) by a third party resulting from or arising out of: (a) exercise of the license under Article 6 by PROMEGA or its AFFILIATES; or (b) the sale or use of any XENOGEN LICENSED PRODUCTS, including claims regarding quality,
performance, safety or operability with XENOGEN’s imaging equipment; except in all cases in (a) and (b) to the extent such Claims result from the gross negligence or intentional misconduct of a Xenogen Indemnitee. This indemnification will
include, but will not be limited to, any product liability arising on account of PROMEGA’s, its AFFILIATES’, or its or their customers’ use of XENOGEN LICENSED PRODUCTS. 
  
 17.3 A Party that intends to claim indemnification under this Article 17 (the “Indemnitee”) promptly shall notify the other Party
(the “Indemnitor”) in writing of any Claim in respect of which the Indemnitee intends to claim the indemnification provided in this Article 17 (INDEMNIFICATION), and the Indemnitor shall have the right to participate in, and, to the extent
the Indemnitor so desires, jointly with any other indemnitor similarly noticed, to assume the defense thereof with counsel selected by the Indemnitor; provided, however, that the Indemnitee shall have the right to retain its own counsel, at its sole
expense, if representation of by the counsel retained by the Indemnitor would be inappropriate due to actual or potential differing interests between the Indemnitee and any other party represented by such counsel in such proceedings. The
indemnification obligations in this Article 17 (INDEMNIFICATION) shall not apply to amounts paid in settlement of any Claim if such settlement is effected without the consent of the Indemnitor, which consent shall not be withheld unreasonably. The
failure to deliver notice to the Indemnitor within a reasonable time after the commencement of any 

  

 Page 21 of 29 

 
such action, if prejudicial to its ability to defend such action, shall relieve the Indemnitor of any liability to the Indemnitee directly attributable to
such failure to deliver notice. The Indemnitee’s omission to deliver notice to the Indemnitor will not relieve the Indemnitor of any liability that it may have to the Indemnitee other than under this Article 17 (INDEMNIFICATION). The
Indemnitee, its employees and agents, shall cooperate fully with the Indemnitor and its legal representatives in the investigation and defense of any action, claim, or liability covered by this indemnification. 
  
 17.4 PROMEGA agrees to indemnify, hold harmless and defend XENOGEN and its officers,
employees and agents, against any and all Claims arising from or out of XENOGEN’s use of the PROMEGA LICENSED TECHNOLOGY supplied to XENOGEN by PROMEGA, except if such Claim relates to issued U.S. Patent Nos. 5,583,024, 5,674,713 and 5,700,673
assigned to the Regents of the University of California or arises from XENOGEN’s use of the PROMEGA LICENSED TECHNOLOGY in a particular method or manner in which it is actually used by XENOGEN, its AFFILIATES, customers or sublicensees.

  
 17.5 XENOGEN promptly shall notify PROMEGA in writing of any liability or
action in respect of which XENOGEN intends to claim the indemnification provided in Paragraph 17.4, and PROMEGA shall have the right to participate in, and, to the extent PROMEGA so desires, jointly with any other indemnitor similarly noticed, to
assume the defense thereof with counsel selected by PROMEGA; provided, however, that XENOGEN shall have the right to retain its own counsel, at its sole expense, if representation of XENOGEN by the counsel retained by PROMEGA would be inappropriate
due to actual or potential differing interests between XENOGEN and any other party represented by such counsel in such proceedings. The indemnity agreement in this Paragraph 17.5 shall not apply to amounts paid in settlement of any loss, claim,
damage, liability or action if such settlement is effected without the consent of PROMEGA, which consent shall not be withheld unreasonably. The failure to deliver notice to PROMEGA within a reasonable time after the commencement of any such action,
if prejudicial to its ability to defend such action, shall relieve PROMEGA of any liability to XENOGEN directly attributable to such failure to deliver notice. XENOGEN’s omission to deliver notice to PROMEGA will not relieve it of any liability
that it may have to XENOGEN otherwise than under this Article 17 (INDEMNIFICATION). XENOGEN, its employees and agents, shall cooperate fully with PROMEGA and its legal representatives in the investigation and defense of any action, claim, or
liability covered by this indemnification. 
  
 MISCELLANEOUS

  
 18.1 The headings of the several sections of this Agreement are inserted
for convenience of reference only and are not intended to be a part of or to affect the meaning or interpretation of this Agreement. 
  
 18.2 This Agreement supersedes all previous agreements, written or oral. This Agreement, including all Appendices attached hereto which are incorporated herein by 

  

 Page 22 of 29 

 
reference, and separate agreements executed pursuant to Paragraph 18.3 below, set forth all the covenants, promises, agreements, warranties, representations,
conditions and understandings between the Parties hereto and supersede and terminate all prior agreements and understandings between the Parties. No amendment or modification hereof shall be valid or binding upon the Parties unless made in writing
and signed on behalf of each Party by an authorized representative. 
  
 18.3 It is
contemplated by the Parties that they may wish to expand the scope of the definition of the PROMEGA LICENSED TECHNOLOGY herein to incorporate other luciferase variants falling within the scope of the claims of additional patent applications and
patents for which PROMEGA is the assignee. Accordingly, the Parties may elect to accomplish such expansion by their express, written, mutual agreement which shall also include the appropriate amendment of “Appendix B - Sublicensed
Technology” attached hereto. 
  
 18.4 This Agreement, including the
performance and enforceability hereof, shall be governed by and construed in accordance with the laws of the State of New York, provided that matters of intellectual property law shall be determined in accordance with the national intellectual
property laws relevant to the intellectual property in question. 
  
 18.5 This
Agreement shall be binding on the Parties and upon their respective heirs, administrators, successors and assigns. 
  
 18.6 This Agreement may not be assigned by either Party without the prior written consent of the other Party; provided that: (i) either Party may assign this Agreement
without the other Party’s consent to an entity that acquires substantially all of the business or assets of the assigning Party (or that portion thereof to which this Agreement relates), in each case whether by merger, acquisition, or otherwise
and the acquiring party assumes this Agreement in writing or by operation of law; and (ii) either Party may assign this Agreement to an AFFILIATE located and incorporated in the United States of America upon notice to the non-assigning Party.

  
 18.7 This Agreement shall not be binding upon the Parties until it has been
signed below on behalf of each Party by an authorized representative, in which event, it shall be effective as of the EFFECTIVE DATE. 
  
 18.8 Should any provision of this Agreement be held invalid, illegal or unenforceable, by a court or other entity of competent jurisdiction, such provision shall be
considered void. All other provisions, rights and obligations shall continue without regard to such provision. 
  
 18.9 No failure or delay by either Party in exercising any of its rights or remedies hereunder shall operate as a waiver thereof, nor shall any single or partial exercise of any such right or remedy preclude any other
or further exercise thereof of any other right or remedy. The rights and remedies of the Parties provided in this Agreement are cumulative and not exclusive of any rights or remedies provided by law. 
  

 Page 23 of 29 

 18.10 The relationship of the Parties established by this Agreement is that of independent contractors, and nothing
contained in this Agreement will be construed to constitute the Parties as partners, joint ventures, co-owners or otherwise as participants in a joint or common undertaking. 
  
 18.11 This Agreement may be executed in counterparts, each of which shall be an original and all of which together shall constitute one and
the same instrument. 
  
 IN WITNESS WHEREOF, the Parties have executed this
Agreement as of the EFFECTIVE DATE. 
  

									
	 PROMEGA: PROMEGA CORP.
	 	 	 	XENOGEN: XENOGEN CORP.
					
	By:	 	 /s/ William. A. Unton
	 	 	 	By:	 	 /s/ Pamela Retlly Contag

	 	 	
	 	 	 	 	 	

					
	 Name:
	 	 William. A. Unton
	 	 	 	 Name:
	 	 Pamela Retlly Contag

					
	 Title:
	 	 President & CEO
	 	 	 	 Title:
	 	 President

					
	 Date:
	 	 May 30, 2003
	 	 	 	 Date:
	 	 May 30, 2003

  

					
	 LEGAL/APPROVED AS TO FORM
	 	 	 	 
			
	/s/ Illegible (INITIALS)	 	 	 	  
	
	 	 	 	 
	5/30/03 (DATE)	 	 	 	[SEAL]

  

 Page 24 of 29 

 APPENDIX A 
 Promega’s Patents 
  

	1.	U.S. Patent No. 5,670,356 entitled, “Modified Luciferase,” Bruce A. Sherf and Keith V. Wood, inventors, assigned to Promega Corporation, and issued September 23, 1997.

  
 There are no related pending applications thereof including
divisionals, substitutions, and continuation-in-part applications; nor are there any corresponding foreign applications or patents. 
  

 Page 25 of 29 

 APPENDIX B 
 SUBLICENSED TECHNOLOGY 
 UCIFERASE GENE DNA SEQUENCE AND CORRESPONDING 
 LUCIFERASE ENZYME AMINO ACID SEQUENCE 
  
 DNA Sequence of the Luciferase Gene Occurring in pGL3 Control Vector (Promega Product #E174) 
  

	1	ATGGAAGACGCCAAAAACATAAAGAAAGGCCCGGCGCCATTCTATCCGCT 

  

	51	GGAAGATGGAACCGCTGGAGAGCAACTGCATAAGGCTATGAAGAGATACG 

  

	101	CCCTGGTTCCTGGAACAATTGCTTTTACAGATGCACATATCGAGGTGGAC 

  

	151	ATCACTTACGCTGAGTACTTCGAAATGTCCGTTCGGTTGGCAGAAGCTAT 

  

	201	GAAACGATATGGGCTGAATACAAATCACAGAATCGTCGTATGCAGTGAAA 

  

	251	ACTCTCTTCAATTCTTTATGCCGGTGTTGGGCGCGTTATTTATCGGAGTT 

  

	301	GCAGTTGCGCCCGCGAACGACATTTATAATGAACGTGAATTGCTCAACAG 

  

	351	TATGGGCATTTCGCAGCCTACCGTGGTGTTCGTTTCCAAAAAGGGGTTGC 

  

	401	AAAAAATTTTGAACGTGCAAAAAAAGCTCCCAATCATCCAAAAAATTATT 

  

	451	ATCATGGATTCTAAAACGGATTACCAGGGATTTCAGTCGATGTACACGTT 

  

	501	CGTCACATCTCATCTACCTCCCGGTTTTAATGAATACGATTTTGTGCCAG 

  

	551	AGTCCTTCGATAGGGACAAGACAATTGCACTGATCATGAACTCCTCTGGA 

  

	601	TCTACTGGTCTGCCTAAAGGTGTCGCTCTGCCTCATAGAACTGCCTGCGT 

  

	651	GAGATTCTCGCATGCCAGAGATCCTATTTTTGGCAATCAAATCATTCCGG 

  

	701	ATACTGCGATTTTAAGTGTTGTTCCATTCCATCACGGTTTTGGAATGTTT 

  

	751	ACTACACTCGGATATTTGATATGTGGATTTCGAGTCGTCTTAATGTATAG 

  

	801	ATTTGAAGAAGAGCTGTTTCTGAGGAGCCTTCAGGATTACAAGATTCAAA 

  

	851	GTGCGCTGCTGGTGCCAACCCTATTCTCCTTCTTCGCCAAAAGCACTCTG 

  

	901	ATTGACAAATACGATTTATCTAATTTACACGAAATTGCTTCTGGTGGCGC 

  

	951	TCCCCTCTCTAAGGAAGTCGGGGAAGCGGTTGCCAAGAGGTTCCATCTGC 

  

	1001	CAGGTATCAGGCAAGGATATGGGCTCACTGAGACTACATCAGCTATTCTG 

  

	1051	ATTACACCCGAGGGGGATGATAAACCGGGCGCGGTCGGTAAAGTTGTTCC 

  

	1101	ATTTTTTGAAGCGAAGGTTGTGGATCTGGATACCGGGAAAACGCTGGGCG 

  

	1151	TTAATCAAAGAGGCGAACTGTGTGTGAGAGGTCCTATGATTATGTCCGGT 

  

	1201	TATGTAAACAATCCGGAAGCGACCAACGCCTTGATTGACAAGGATGGATG 

  

	1251	GCTACATTCTGGAGACATAGCTTACTGGGACGAAGACGAACACTTCTTCA 

  

	1301	TCGTTGACCGCCTGAAGTCTCTGATTAAGTACAAAGGCTATCAGGTGGCT 

  

	1351	CCCGCTGAATTGGAATCCATCTTGCTCCAACACCCCAACATCTTCGACGC 

  

	1401	AGGTGTCGCAGGTCTTCCCGACGATGACGCCGGTGAACTTCCCGCCGCCG 

  

	1451	TTGTTGTTTTGGAGCACGGAAAGACGATGACGGAAAAAGAGATCGTGGAT 

  

	1501	TACGTCGCCAGTCAAGTAACAACCGCGAAAAAGTTGCGCGGAGGAGTTGT 

  

	1551	GTTTGTGGACGAAGTACCGAAAGGTCTTACCGGAAAACTCGACGCAAGAA 

  

	1601	AAATCAGAGAGATCCTCATAAAGGCCAAGAAGGGCGGAAAGATCGCCGTG* 

  
 Corresponding pGL3 Luciferase Amino Acid Sequence 
  

	1	MEDAKNIKKGPAPFYPLEDGTAGEQLHKAMKRYALVPGTIAFTDAHIEVDITYAEYFEMS 

  

	61	VRLAEAMKRYGLNTNHRIVVCSENSLQFFMPVLGALFIGVAVAPANDIYNERELLNSMGI 

  

	121	SQPTVVFVSKKGLQKILNVQKKLPIIQKIIIMDSKTDYQGFQSMYTFVTSHLPPGFNEYD 

  

	181	FVPESFDRDKTIALIMNSSGSTGLPKGVALPHRTACVRFSHARDPIFGNQIIPDTAILSV 

  

	241	VPFHHGFGMFTTLGYLICGFRVVLMYRFEEELFLRSLQDYKIQSALLVPTLFSFFAKSTL 

  

	301	IDKYDLSNLHEIASGGAPLSKEVGEAVAKRFHLPGIRQGYGLTETTSAILITPEGDDKPG 

  

	361	AVGKVVPFFEAKVVDLDTGKTLGVNQRGELCVRGPMIMSGYVNNPEATNALIDKDGWLHS 

  

	421	GDIAYWDEDEHFFIVDRLKSLIKYKGYQVAPAELESILLQHPNIFDAGVAGLPDDDAGEL 

  

	481	PAAVVVLEHGKTMTEKEIVDYVASQVTTAKKLRGGVVFVDEVPKGLTGKLDARKIREILI 

  

	541	KAKKGGKIAV* 

  

 Page 26 of 29 

 APPENDIX C 
 LEFT BLANK INTENTIONALLY 
  

 Page 27 of 29 

 APPENDIX D 
 Xenogen’s Non-Imaging Patents 
  
 PCT
Application WO 00/54581 published 21 September, 2000, entitled “Animal Models and Methods for Sepsis”. 
  
 PCT Application WO 97/40381 published 30 October, 1997, entitled “Biodetectors Targeted to Specific Ligands”. 
  

 Page 28 of 29 

 APPENDIX E 
 Xenogen’s Imaging Patents 
  
 U.S.
Patent No. 5,650,135 issued July 22, 1997, entitled, “Non-invasive Localization of a Light-Emitting Conjugate in a Mammal”. 
  
 PCT Application WO 00/36106 published 22 June, 2000, entitled “Non-invasive Evaluation of Physiological Response in a Mammal”. 
  
 PCT Application WO 97/18841 published 29 May, 1997, entitled “Non-invasive Localization
of a Light-Emitting Conjugate in a Mammal”. 
  

 Page 29 of 29

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00065-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00065-of-00352.parquet"}]]